Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma.
Orlow I, Sadeghi KD, Edmiston SN, Kenney JM, Lezcano C, Wilmott JS, Cust AE, Scolyer RA, Mann GJ, Lee TK, Burke H, Jakrot V, Shang P, Ferguson PM, Boyce TW, Ko JS, Ngo P, Funchain P, Rees JR, O'Connell K, Hao H, Parrish E, Conway K, Googe PB, Ollila DW, Moschos SJ, Hernando E, Hanniford D, Argibay D, Amos CI, Lee JE, Osman I, Luo L, Kuan PF, Aurora A, Gould Rothberg BE, Bosenberg MW, Gerstenblith MR, Thompson C, Bogner PN, Gorlov IP, Holmen SL, Brunsgaard EK, Saenger YM, Shen R, Seshan V, Nagore E, Ernstoff MS, Busam KJ, Begg CB, Thomas NE, Berwick M; InterMEL Consortium. Orlow I, et al. Among authors: saenger ym. PLoS One. 2023 Apr 3;18(4):e0269324. doi: 10.1371/journal.pone.0269324. eCollection 2023. PLoS One. 2023. PMID: 37011054 Free PMC article.
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.
Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gérard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, Rui S, Ernstoff MS, Taback B, Pabla S, Chang R, Lee SJ, Krolewski JJ, Morrison C, Horst BA, Saenger YM. Gartrell RD, et al. Among authors: saenger ym. Clin Cancer Res. 2019 Apr 15;25(8):2494-2502. doi: 10.1158/1078-0432.CCR-18-2847. Epub 2019 Jan 15. Clin Cancer Res. 2019. PMID: 30647081 Free PMC article.
Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.
Luo L, Shen R, Arora A, Orlow I, Busam KJ, Lezcano C, Lee TK, Hernando E, Gorlov I, Amos C, Ernstoff MS, Seshan VE, Cust AE, Wilmott J, Scolyer RA, Mann G, Nagore E, Funchain P, Ko J, Ngo P, Edmiston SN, Conway K, Googe PB, Ollila D, Lee JE, Fang S, Rees JR, Thompson CL, Gerstenblith M, Bosenberg M, Gould Rothberg B, Osman I, Saenger Y, Reynolds AZ, Schwartz M, Boyce T, Holmen S, Brunsgaard E, Bogner P, Kuan PF, Wiggins C, Thomas NE, Begg CB, Berwick M; InterMEL. Luo L, et al. Pigment Cell Melanoma Res. 2022 Nov;35(6):605-612. doi: 10.1111/pcmr.13058. Epub 2022 Aug 12. Pigment Cell Melanoma Res. 2022. PMID: 35876628 Free PMC article.
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.
Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. Sivendran S, et al. Among authors: saenger ym. J Invest Dermatol. 2014 Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12. J Invest Dermatol. 2014. PMID: 24522433 Free PMC article.
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Morrison C, Pabla S, Conroy JM, Nesline MK, Glenn ST, Dressman D, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Qin M, Wang Y, Lenzo FL, Omilian A, Bshara W, Zibelman M, Ghatalia P, Dragnev K, Shirai K, Madden KG, Tafe LJ, Shah N, Kasuganti D, de la Cruz-Merino L, Araujo I, Saenger Y, Bogardus M, Villalona-Calero M, Diaz Z, Day R, Eisenberg M, Anderson SM, Puzanov I, Galluzzi L, Gardner M, Ernstoff MS. Morrison C, et al. J Immunother Cancer. 2018 May 9;6(1):32. doi: 10.1186/s40425-018-0344-8. J Immunother Cancer. 2018. PMID: 29743104 Free PMC article.
Melanoma immunotherapy.
Sivendran S, Glodny B, Pan M, Merad M, Saenger Y. Sivendran S, et al. Mt Sinai J Med. 2010 Nov-Dec;77(6):620-42. doi: 10.1002/msj.20215. Mt Sinai J Med. 2010. PMID: 21105125 Review.
Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjatic S, Remark R, Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA, Birge MB, Phelps RG, Saenger YM. de Moll EH, et al. Among authors: saenger ym. Cancer Immunol Immunother. 2015 Sep;64(9):1193-203. doi: 10.1007/s00262-015-1726-0. Epub 2015 Jun 16. Cancer Immunol Immunother. 2015. PMID: 26076664 Free PMC article.
The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY, Lopez AT, Gartrell RD, Komatsubara KM, Bogardus M, Rao N, Chen C, Hart TD, Enzler T, Rizk EM, Pradhan JS, Marks DK, Geskin LJ, Saenger YM. Bayan CY, et al. Among authors: saenger ym. Curr Oncol Rep. 2018 Aug 25;20(10):80. doi: 10.1007/s11912-018-0729-3. Curr Oncol Rep. 2018. PMID: 30145781 Free PMC article. Review.
61 results